poisar

Stocks · News reference

Shares of mRNA cancer vaccine-related companies are trading higher amid sympathy with Merck and Moderna after they announced that intismeran autogene with KEYTRUDA yielded recurrence-free survival in patients with completely resected stage IIB-IV melanoma.

BenzingaBenzinga News-desk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncDelveinsight

    NSCLC Treatment Landscape Shifts as ESMO 2026 Spotlights MET, KRAS, and TROP2 Advances, Says DelveInsight

    The non-small cell lung cancer market is shifting toward precision, biomarker-guided treatment sequencing. ESMO 2026 presented Phase III data showing savolitinib plus osimertinib improved survival in MET-altered EGFR-mutated NSCLC, divarasib outperformed approved KRAS G12C inhibitors, and TROP2-directed ADCs demonstrated durable gains. The 7MM NSCLC market is projected to double from USD 33 billion in 2025 to USD 67 billion by 2036, driven by expanded screening, biomarker-driven therapies, and label expansions into earlier-stage disease.

  2. Globenewswire IncPrecedence Research

    Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing

    The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.

  3. Globenewswire IncSellas Life Sciences Group, Inc.

    SELLAS anuncia resultados positivos del ensayo pivotal de fase 3 REGAL, que demuestran que la vacuna inmunoterapéutica contra el cáncer galinpepimut-S (GPS) produjo una mejora estadísticamente significativa y clínicamente relevante de la supervivencia global en pacientes con leucemia mieloide aguda

    SELLAS Life Sciences announced positive results from its Phase 3 REGAL trial showing that galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, demonstrated a statistically significant 41% reduction in risk of death in acute myeloid leukemia patients, with median overall survival of 24.0 months versus 14.7 months with standard treatment. The company plans to meet with the FDA and submit a biologics license application in the first half of 2027.